Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

Number_4 Apr. 25 at 8:40 AM

$ACHV ACHV's new CEO Goldberg sits on the BOD at TARS. So I naturally did some work on that name. TARS is as interesting a story as ACHV. Maybe more so. Check it out and provide some input. Also, very long VKTX. These are 3 very long term positions where I plan to let the story unfold. All 3 names- TAKEN OVER by BP within 24 months, IMO. Good luck.

0 · Reply

Number_4 Apr. 25 at 8:35 AM

$ACHV No one is talking about the huge opportunity in cessation from ZYN pouches. Please shorts, keep leaning on this and fill the Gap with all your CRL bs. It's priced in.....but I want 100,000+ more shares at around $3.65-$3.70.

0 · Reply

MrTicker Apr. 24 at 10:03 PM

$ACHV recent 13D, TPG owns 13.7 million shares , roughly 12.6%

1 · Reply

MrTicker Apr. 24 at 9:56 PM

$ACHV Form SCHEDULE 13D ACHIEVE LIFE SCIENCES, Filed by: TPG GP A, LLC 10K WIZARD 4:03 PM ET 4/24/2026 http://archive.fast-edgar.com/20260424/AVZZT22CZ22TO2FZ2Z2M22Z2IS5PZZ2SZ382 Filed on: April 24, 2026

0 · Reply

Traildog19 Apr. 24 at 7:41 PM

$ACHV summer grind down to fill the gap @. 3.10 after CRL is official and Adare mfg preparedness questions grow.

1 · Reply

kuboss Apr. 24 at 4:52 PM

$ACHV The Intellectual Property and Technology Companies teams advised Marshall Wace on a securities purchase agreement with Achieve Life Sciences, Inc. https://www.goodwinlaw.com/en/news-and-events/news/2026/04/announcements-technology-ip-goodwin-advises-marshall-wace So IMO, Masterful asset scrubbing and a final shakeout are in progress😉

1 · Reply

OfficialStocktwitsUser Apr. 23 at 12:19 AM

$ACHV RSI: 67.87, MACD: 0.1475 Vol: 0.68, MA20: 3.51, MA50: 3.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

NYPD Apr. 22 at 10:47 AM

$ACHV Achieve Life Sciences Rated New Buy at Canaccord; PT $13 By Bloomberg Automation (Bloomberg) -- Canaccord Genuity initiated coverage of Achieve Life Sciences Inc. with a recommendation of buy. PT set to $13, implies a 206% increase from last price.

0 · Reply

DragonAlgo Apr. 22 at 10:10 AM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-05-15 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.27 Stop: $0.19 TP1: $0.35 TP2: $0.46 TP3: $0.65 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

markwall Apr. 22 at 5:19 AM

$ACHV Do you guys think the company is worth 133% more in a buyout situation with vaping and smoking FDA approval as opposed to just having smoking approval? Is the massive dilution worth it going into a potential buyout situation next year with both approvals?

3 · Reply

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Apr 16, 2026, 8:53 AM EDT - 9 days ago

Achieve Life Sciences Announces Up to $354 Million Private Placement

Apr 15, 2026, 8:00 AM EDT - 10 days ago

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Mar 26, 2026, 8:58 AM EDT - 4 weeks ago

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Mar 26, 2026, 8:30 AM EDT - 4 weeks ago

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Mar 24, 2026, 2:23 PM EDT - 4 weeks ago

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 4 weeks ago

Achieve Life Sciences Earnings Call Transcript: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 4 weeks ago

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:30 AM EDT - 5 weeks ago

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

Mar 4, 2026, 8:00 AM EST - 7 weeks ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

Jan 30, 2026, 4:05 PM EST - 3 months ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Jan 12, 2026, 8:47 AM EST - 3 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Dec 17, 2025, 4:11 PM EST - 4 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Nov 6, 2025, 8:30 AM EST - 6 months ago

Achieve Life Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 6 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 17, 2025, 7:30 AM EDT - 6 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 7 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 8 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Achieve Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 8 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 7, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 9 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jun 30, 2025, 7:52 PM EDT - 10 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 10 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 10 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 10 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 4, 2025, 5:30 PM EDT - 11 months ago

Achieve Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 1 year ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 12, 2025, 11:30 AM EDT - 1 year ago

Achieve Life Sciences Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Achieve Life Sciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 7, 2024, 4:30 PM EST - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q3 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Oct 1, 2024, 8:45 AM EDT - 1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q2 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Achieve Life Sciences Earnings Call Transcript: Q1 2024

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Achieve Life Sciences Earnings Call Transcript: Q4 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Achieve Life Sciences Earnings Call Transcript: Q3 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Achieve Life Sciences Earnings Call Transcript: Q2 2023

May 9, 2023, 4:30 PM EDT - 3 years ago

Achieve Life Sciences Earnings Call Transcript: Q1 2023

Mar 16, 2023, 4:30 PM EDT - 3 years ago

Achieve Life Sciences Earnings Call Transcript: Q4 2022

Nov 14, 2022, 4:30 PM EST - 3 years ago

Achieve Life Sciences Earnings Call Transcript: Q3 2022

Aug 11, 2022, 9:00 AM EDT - 4 years ago

Achieve Life Sciences Earnings Call Transcript: Q2 2022

Number_4 Apr. 25 at 8:40 AM

0 · Reply

Number_4 Apr. 25 at 8:35 AM

0 · Reply

MrTicker Apr. 24 at 10:03 PM

$ACHV recent 13D, TPG owns 13.7 million shares , roughly 12.6%

1 · Reply

MrTicker Apr. 24 at 9:56 PM

0 · Reply

Traildog19 Apr. 24 at 7:41 PM

$ACHV summer grind down to fill the gap @. 3.10 after CRL is official and Adare mfg preparedness questions grow.

1 · Reply

kuboss Apr. 24 at 4:52 PM

1 · Reply

OfficialStocktwitsUser Apr. 23 at 12:19 AM

0 · Reply

NYPD Apr. 22 at 10:47 AM

0 · Reply

DragonAlgo Apr. 22 at 10:10 AM

0 · Reply

markwall Apr. 22 at 5:19 AM

3 · Reply

Nat21 Apr. 22 at 2:50 AM

$ONCO institutions has been loading last month $NNOX $ACHV

0 · Reply

bobtheknob Apr. 21 at 10:26 PM

$ACHV Holey moley

1 · Reply

Traildog19 Apr. 21 at 4:15 PM

$ACHV SSR in effect to pause selloff.

1 · Reply

backtesttrend Apr. 21 at 3:56 PM

$ACHV Added a small position today around 4.05 alongside existing call exposure. For me, the more attractive add zone would still be in the 3.5–3.6 area if we get a pullback. That’s where risk/reward starts to look cleaner on the chart. Managing sizing here and staying flexible depending on how price reacts. 👉If this helps, tap @backtesttrend

0 · Reply

notreload_ai Apr. 21 at 10:04 AM

$ACHV gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026. https://notreload.xyz/xy/achv-stock-buy-rating-for-cytisinicline/

0 · Reply

Traildog19 Apr. 20 at 8:09 PM

$ACHV woah! Warrant holders bringing this back down to 3.63 where offering shares were priced. NFW this stays above that level since CRL inbound and no good news til NDA resubmit late Q4. Gap definitely gets filled IMO. Short term (6 mos)very

3 · Reply

Sieppo Apr. 20 at 8:09 PM

$ACHV She always craps the bed... An investment here is likely a 1-2year bet on a successful commercialization, which always are rocky and take a lot of money. Wouldn't be surprised if they diluted again in a year. But so far it's of course derisked if the FDA doesn't surprise.

2 · Reply

DragonAlgo Apr. 20 at 7:59 PM

🐉 $ACHV PUT — DragonAlgo® Signal Contract: ACHV PUT Expiry: 2026-06-18 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $3.20 Stop: $2.30 TP1: $4.16 TP2: $5.44 TP3: $7.68 🔗 https://dragonalgo.com

0 · Reply

jrw06 Apr. 20 at 6:39 PM

$ACHV should’ve sold!

2 · Reply

RaphaelRapoport Apr. 20 at 6:35 PM

$ACHV Back to 3.5 we go or less. Time to get ready to buy :)

0 · Reply

LagerHound Apr. 20 at 2:22 PM

$ACHV the pump is over. Algos flipped to sell side in anticipation of CRL (PR by Co. Expecting CRL) will grind lower, as NDA redubmit takes til Q4/26 WTF. retest3.50 support. Short term.

1 · Reply

BG_BULL Apr. 19 at 1:53 PM

$ACHV Maybe we just went back to this channel 😉

1 · Reply

Market Cap	220.92M
Revenue (ttm)	0.00
Net Income (ttm)	-54.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.25

Volume	792,300
Avg Vol	1,040,994
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	42%
Beta	1.96
Analysts	Strong Sell
Price Target	$14.62